These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30967233)

  • 1. In Regard to Bryant et al.
    Hurmuz P; Ozyigit G
    Int J Radiat Oncol Biol Phys; 2019 May; 104(1):224-225. PubMed ID: 30967233
    [No Abstract]   [Full Text] [Related]  

  • 2. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Greil et al.: Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals (Urology 2009;73:631-634).
    Tan WW
    Urology; 2009 Jun; 73(6):1427-8. PubMed ID: 19482168
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Masashi Yano, Takashi Imamoto, Hiroyoshi Suzuki et Al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur urol 2007;51:375-80.
    Morgentaler A
    Eur Urol; 2007 Jul; 52(1):292; author reply 293-4. PubMed ID: 17400361
    [No Abstract]   [Full Text] [Related]  

  • 5. Testosterone therapy in the ageing male: what about the prostate?
    Schultheiss D; Machtens S; Jonas U
    Andrologia; 2004 Dec; 36(6):355-65. PubMed ID: 15541051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of peripheral testosterone matabolism after induced hypoprolactinemia in patients with prostatic carcinoma.
    Jacobi GH; Altwein JE; Hohenfellner R
    Klin Wochenschr; 1979 Jan; 57(1):49-51. PubMed ID: 759717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Michael J. Morris, Daisy Huang, William K. Kelly, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44.
    Drewa T; Chlosta P
    Eur Urol; 2010 Feb; 57(2):e18-9; author reply e20. PubMed ID: 19853990
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e23; author reply e24. PubMed ID: 19586711
    [No Abstract]   [Full Text] [Related]  

  • 9. In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
    Prout GR; Kliman B; Daly JJ; Maclaughlin RA; Griffin PP
    J Urol; 1976 Nov; 116(5):603-10. PubMed ID: 62062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.
    Røhl HF; Beuke HP
    Scand J Urol Nephrol; 1992; 26(1):11-4. PubMed ID: 1631501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.
    Friedman AE
    Eur Urol; 2009 Nov; 56(5):e36; author reply e37. PubMed ID: 19683856
    [No Abstract]   [Full Text] [Related]  

  • 12. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia.
    Rhoden EL; Morgentaler A
    J Urol; 2003 Dec; 170(6 Pt 1):2348-51. PubMed ID: 14634413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLASMA TESTOSTERONE LEVELS IN PATIENTS WITH PROSTATIC CARCINOMA.
    KENT JR; YOUNG HH
    Surg Forum; 1964; 15():485-6. PubMed ID: 14193458
    [No Abstract]   [Full Text] [Related]  

  • 14. [Testosterone substitution with special regard to prostate cancer].
    Beintker M; Behre H
    Urologe A; 2008 Dec; 47(12):1588-91. PubMed ID: 18931991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum of patients with prostatic cancer or benign prostatic hypertrophy contains nonpolar testosterone.
    Addo SB; Holland JF; Kirschenbaum A; Mandeli J; Hollander VP
    Steroids; 1990 Nov; 55(11):491-4. PubMed ID: 1706116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary testosterone in prostatic carcinoma.
    Navarro MA; Aguiló F; Villabona CM; Torrecilla C; Bonnin R
    Br J Urol; 1989 Mar; 63(3):306-8. PubMed ID: 2702429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of 3H-testosterone to dihydrotestosterone in human hypertrophic prostatic tissue.
    Baranowska B; Zgliczyński S
    Nuklearmedizin; 1979; 18(6):297-9. PubMed ID: 94161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of castration on adrenal testosterone secretion in men with prostatic carcinoma.
    Sanford EJ; Paulson DF; Rohner TJ; Santen RJ; Bardin CW
    J Urol; 1977 Dec; 118(6):1019-21. PubMed ID: 72830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaerobic glycolysis of human benign prostatic hypertrophy slices: inhibition by testosterone.
    McDONALD DF; LATTA MJ
    J Appl Physiol; 1954 Nov; 7(3):325-8. PubMed ID: 13211518
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic factors in metastatic prostate cancer.
    Matzkin H; Perito PE; Soloway MS
    Cancer; 1993 Dec; 72(12 Suppl):3788-92. PubMed ID: 7504577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.